Media & Resources

The International AIDS Vaccine Initiative (IAVI) has named Lipoxen, PLC, a leading UK-based biopharmaceutical company, and Strand Life Sciences, a premier life sciences company based in Bangalore, India, as the latest award recipients of the organization’s Innovation Fund—a new seed capital fund designed to bring novel, early-stage technologies to the field of AIDS vaccine research.…

Debunking the Myth 25 Years Later:  An AIDS Vaccine is Possible and Still Urgently Needed  NEW YORK, NY, May 16, 2008 —Twenty-five years since the discovery of HIV, the world has made considerable advances in addressing the AIDS pandemic. Scientists have learned a tremendous amount about HIV, perhaps more than any other pathogen, and have…

National Community Fund and Greystone Capital CDE Provide Tax Credit Financing for Construction of AIDS Vaccine Development Lab at New York’s Brooklyn Army Terminal  NEW YORK, April 25, 2008– National Community Fund I, LLC (NCF) and Greystone CDE, LLC (Greystone), closed New Markets Tax Credit (NMTC) financing for a new AIDS Vaccine Development Laboratory for…

Leading HIV Researchers to Collaborate on Vaccine Development DURHAM, NC, and NEW YORK, NY – Two global research organizations dedicated to designing a vaccine against HIV – the International AIDS Vaccine Initiative (IAVI), and the Center for HIV/AIDS Vaccine Immunology (CHAVI) – have signed an agreement to work together to address major biological questions that…

Study Shows Male Circumcision Provides No Protection against HIV for Women; Another Says It Reduces Genital Infections in Men and Women  According to a new study, male circumcision, which reduces by about 60 percent the likelihood that a male will become HIV infected through sex with an HIV-infected female, provided no benefit to the HIV-uninfected…

IAVI’s Innovation Fund targets unconventional ideas for AIDS vaccine development NEW YORK, March 3, 2008 — The International AIDS Vaccine Initiative (IAVI) today announced the first award from its Innovation Fund, a new funding mechanism that will identify and advance potential breakthrough technologies and apply them in the AIDS vaccine research field. This initial project…

Phase III Microbicide Clinical Trial Shows Carraguard is Safe But Not Effective against HIV Transmission in Women  A Phase III clinical trial of the microbicide Carraguard has found that although the vaginal gel, designed to be applied before intercourse, proved safe it did not prevent male-to-female transmission of HIV during vaginal intercourse. Carraguard, which was…

February 15, 2008 – At the annual conference of the American Association for the Advancement of Science, the organization’s president, eminent scientist and Nobel laureate David Baltimore, commented on February 14 in Boston on the current state of AIDS vaccine research. Professor Baltimore expressed concern at the field’s lack of success so far in developing…